Mitochondrial Variations in Non-Small Cell Lung Cancer (NSCLC) Survival

被引:0
|
作者
Wang, Zhaoxi [1 ]
Choi, Sojung [2 ]
Lee, Jinseon [2 ]
Huang, Yen-Tsung [5 ]
Chen, Feng [3 ]
Zhao, Yang [3 ]
Lin, Xihong [4 ]
Neuberg, Donna [4 ]
Kim, Jhingook [2 ]
Christiani, David C. [2 ]
机构
[1] Harvard Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA
[2] Samsung Med Ctr, Dept Thorac Surg, Seoul, South Korea
[3] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
[4] Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA
[5] Brown Univ, Providence, RI 02912 USA
来源
CANCER INFORMATICS | 2015年 / 14卷
关键词
mitochondria genome; mitochondria mutations; lung cancer survival; haplogroup; mitochondrial genome resequencing;
D O I
10.4137/CIn.s13976
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutations in the mtDNA genome have long been suspected to play an important role in cancer. Although most cancer cells harbor mtDNA mutations, the question of whether such mutations are associated with clinical prognosis of lung cancer remains unclear. We resequenced the entire mitochondrial genomes of tumor tissue from a population of 250 Korean patients with non-small cell lung cancer (NSCLC). Our analysis revealed that the haplogroup (D/D4) was associated with worse overall survival (OS) of early-stage NSCLC [adjusted hazard ratio (AHR), 1.95; 95% CI, 1.14-3.33; P-trend = 0.03]. By comparing the mtDNA variations between NSCLC tissues and matched blood samples, we found that haplogroups M/N and/or D/D4 were hotspots for somatic mutations, suggesting a more complicated mechanism of mtDNA somatic mutations other than the commonly accepted mechanism of sequential accumulation of mtDNA mutations.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [1] SURVIVAL OF PATIENTS WITH BRAIN METASTASES AND NON-SMALL CELL LUNG CANCER (NSCLC)
    Randhawa, J. K.
    Patel, S. P.
    Stokes, T. C.
    [J]. THORAX, 2009, 64 : A148 - A148
  • [2] β-catenin in non-small cell lung cancer (NSCLC)
    Swinson, DEB
    Lolljee, J
    Edwards, JG
    Jones, JL
    Cox, G
    Richardson, D
    O'Byrne, KJ
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 : S59 - S60
  • [3] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    [J]. JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
  • [4] Genotyping Non-Small Cell Lung Cancer (NSCLC)
    Delia Campos-Parra, Alma
    Cruz-Rico, Graciela
    Arrieta, Oscar
    [J]. GACETA MEXICANA DE ONCOLOGIA, 2012, 11 (01): : 35 - 44
  • [5] Micrometastases in non-small cell lung cancer (NSCLC)
    Passlick, B
    [J]. LUNG CANCER, 2001, 34 : S25 - S29
  • [6] Immunotherapy for non-small cell lung cancer (NSCLC)
    Frost, Nikolaj
    Reck, Martin
    [J]. INNERE MEDIZIN, 2022, 63 (07): : 709 - 716
  • [7] BRCAness in non-small cell lung cancer (NSCLC).
    Waqar, Saiama Naheed
    Devarakonda, Siddhartha H. K.
    Michel, Loren S.
    Maggi, Leonard B.
    Watson, Mark
    Guebert, Kalin
    Carpenter, Danielle
    Sleckman, Barry P.
    Govindan, Ramaswamy
    Morgensztern, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
    Christian Manegold
    Petr Zatloukal
    Kurt Krejcy
    Johannes Blatter
    [J]. Investigational New Drugs, 2000, 18 : 29 - 42
  • [9] Eicosanoids in non-small cell lung cancer (NSCLC)
    Johnson, D. H.
    Horn, L.
    Zhao, Z.
    Milne, G.
    Morrow, J.
    Sandler, A.
    Shyr, Y.
    Carbone, D. P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Gemcitabine in non-small cell lung cancer (NSCLC)
    Manegold, C
    Zatloukal, P
    Krejcy, K
    Blatter, J
    [J]. INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) : 29 - 42